Heat Intolerance- A Lesson From Global Genomic Response in Lymphocytes
Following Study: Heat Intolerance- A Lesson From Global Genomic Response in Lymphocytes
Sponsor: Medical Corps, Israel Defense Force
Listed as NCT00918359, this observational or N/A phase trial focuses on Gene Expression and Genomic Markers for Predisposition of Heat Intolerance and remains ongoing. Sponsored by Medical Corps, Israel Defense Force, it has been updated 10 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status NA
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical Corps, Israel Defense Force
For direct contact, visit the study record on ClinicalTrials.gov .